Health Canada has authorized Eli Lilly’s Foundayo, a once-daily GLP-1 pill for weight loss, according to The Canadian Press.
Foundayo is approved for adults with obesity, and for overweight adults with at least one related medical problem such as high blood pressure or sleep apnea. It is also approved to help treat Type 2 diabetes. Health Canada authorized the drug on Nov. 13, and Eli Lilly spokesperson Ethan Pigott said the company expects the pills to reach pharmacies in January.
Until now, GLP-1 weight-loss drugs in Canada have been weekly injections. Eli Lilly also makes the injectables Mounjaro and Zepbound, which contain tirzepatide, while Novo Nordisk makes Ozempic and Wegovy, which contain semaglutide. Novo Nordisk’s Rybelsus is already sold in Canada as a pill, but it is approved only for managing Type 2 diabetes, not for weight loss.
Foundayo’s active ingredient is orforglipron, a non-peptide GLP-1 receptor agonist. Dr. Ehud Ur, a Vancouver endocrinologist who is not associated with either drugmaker, told The Canadian Press that because it is a smaller molecule than semaglutide and tirzepatide, orforglipron can be absorbed without being broken down by the digestive system. “It seems to be just as good as if not better” for weight loss, he said, adding that some patients may prefer a pill to an injection.
Ur said whether he would prescribe it depends on the patient, partly because he is still waiting for trial results on whether orforglipron has a cardiovascular benefit, as semaglutide and tirzepatide do. The most common side effects of GLP-1 drugs, injectable and oral, are nausea and vomiting.
A second pill could follow. Novo Nordisk’s Wegovy pill, a semaglutide tablet, is awaiting Health Canada approval, Novo Nordisk spokesperson Kate Hanna said. Both it and Foundayo are already approved and available in the United States.
No price was given for Foundayo. Public coverage of diabetes drugs differs across the country, as our guide to what four jurisdictions cover under pharmacare shows. Earlier this year we reported on patients without drug coverage awaiting generic Ozempic, and in October on the World Health Organization’s advice on weight-loss drugs for children. GLP-1 drugs should be used with diet and exercise, experts say.
This report is based on reporting by The Canadian Press, first published Nov. 18, 2026.
If you find reporting like this useful, consider supporting Canada News Media, an independently owned Canadian newsroom.
Follow Canada News Media
Get the day's top Canadian stories and our two daily 60-second news videos wherever you scroll.
X Threads Facebook Instagram LinkedIn TikTok YouTube Pinterest Reddit Substack Flipboard Newsletter RSS













